๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 13 Shenzhen 2 Luoyang 2 Zhengzhou 1 Nanchang 1
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing13 Shenzhen2 Luoyang2 Zhengzhou1 Nanchang1
All 18 locations
Target enrolment
to

Trials with a site in Beijing

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus Erythematosus
NCT07814664Systemic Lupus Erthematosus
Chinese SLE Treatment And Research Group
Phase 2/3
294
Beijing
2026-10-15
Not yet open
Treatment Strategy for Patients With RA-ILD
NCT07643038Rheumatoid Arthritis Associated Interstitial Lung Disease
Chinese SLE Treatment And Research Group
Phase 4
204
Luoyang, Beijing, Changchun, Chongqing, Dalian, Handan, Hangzhou, Hefei
2026-09-20
Active, closed
Efficacy and Safety of IL-1 Inhibitors in Mild to Moderate Systemic Lupus Erythematosus
NCT07381465Lupus Erythematosus, Systemic
Chinese SLE Treatment And Research Group
Phase 4
15
Beijing
2026-06-16
Recruiting
Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
NCT07657793Systemic Lupus Erythematosus, Immune Thrombocytopenia
Chinese SLE Treatment And Research Group
Phase 2/3
164
Beijing
2026-06-07
Not yet open
Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis
NCT07451665Takayasu Arteritis (TAK)
Chinese SLE Treatment And Research Group
Phase 4
180
Beijing, Guanzhou, Shenzhen, Nanning, Jiaozuo, Luoyang, Wuhan, Nanjing
2026-04-01
Not yet open
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis
NCT07013838Takayasu Arteritis (TAK)
Chinese SLE Treatment And Research Group
Phase 4
50
Beijing
2025-06-15
Not yet open
Telitacicept for the Treatment of Refractory RA
NCT07008196Rheumatoid Arthritis (RA)
Chinese SLE Treatment And Research Group
Phase 4
30
Beijing
2025-06-10
Recruiting
Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus
NCT06881290Lupus Erythematosus, Systemic
Chinese SLE Treatment And Research Group
Phase 1
20
Beijing
2025-05-19
Recruiting
Chinese Rheumatism Biobank(CRB)
NCT06887517Lupus Erythematosus, Systemic
Chinese SLE Treatment And Research Group
Observational
300
Beijing
2025-02-10
Recruiting
Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis
NCT06167174Lupus Nephritis
Chinese SLE Treatment And Research Group
Observational
100
Beijing
2023-12-05
Recruiting
Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)
NCT05962840ANCA Associated Vasculitis
Chinese SLE Treatment And Research Group
Phase 4
40
Beijing
2023-06-29
Recruiting
Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)
NCT05965284ANCA-associated Vasculitis, Maintenance Therapy
Chinese SLE Treatment And Research Group
Phase 4
40
Beijing
2023-03-09
Active, closed
Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus
NCT04582136Systemic Lupus Erythematosus
Chinese SLE Treatment And Research Group
Phase 3
146
Beijing, Shenzhen, Zhengzhou, Nanchang, Shenyang, Kunming
2021-03-04
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

6 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 13 studies
PhaseStudiesRecruitingShare
Phase 47253.8%
Observational2215.4%
Phase 2/32115.4%
Phase 1117.7%
Phase 3107.7%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Chinese SLE Treatment And Research Group136
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.